InVivo Therapeutics Holdings Corp. (NVIV), a pioneering
biomaterials company with unique technologies for drug delivery with a
focus on treatment of spinal cord injuries, today announced that
Christopher McNulty has been appointed as Vice President, Business
Development.
Most recently, Mr. McNulty served as Senior Director of Business
Development at Repligen Corporation, where his responsibilities included
out-licensing programs for rare neurodegenerative diseases. Previously,
he was Director of Corporate Development at Seventh Sense Biosystems and
Associate Director of Business Development and Alliance Management at
Genzyme Corporation. While at Genzyme, he led business development
activities in the area of neurology. Before joining Genzyme, Mr. McNulty
held technical roles at Transform Pharmaceuticals and Cereon Genomics.
He has an MBA from Harvard Business School, and BS and MEng degrees from
MIT, where he performed research on biological hydrogels.
Michael Astrue, the interim CEO of InVivo, stated, “Going forward we
expect our growth to be driven primarily by our success as a drug
delivery company. In particular, our proprietary technology that can
deliver proteins and other molecules locally on a time-release basis can
provide significant value to most major pharmaceutical companies and
biotech companies. Chris will be a key part of our transformation.”
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. focuses on utilizing polymers as a
platform technology to develop treatments for serious diseases and
conditions, including improving function in individuals paralyzed as a
result of traumatic spinal cord injury. The Company was founded in 2005
with proprietary technology co-invented by Robert Langer, ScD.,
Professor at Massachusetts Institute of Technology, and Joseph P.
Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In
2011 the Company earned the David S. Apple Award from the American
Spinal Injury Association for its outstanding contribution to spinal
cord injury medicine. The publicly traded company is headquartered in
Cambridge, MA. For more details, visit, www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements within the
meaning of the federal securities laws. Any forward-looking statements
contained herein are based on current expectations, but are subject to a
number of risks and uncertainties, and include statements regarding the
Company’s expectations with respect to the commencement of human
clinical trials for the scaffold product and with respect to possible
partnerships. The factors that could cause actual future results to
differ materially from current expectations include, but are not limited
to, risks and uncertainties relating to the identification of
appropriate clinical sites; the Institutional Review Board process; the
Company’s ability to enter into partnerships; the Company’s ability to
obtain FDA approval to commercialize its products; the Company’s ability
to develop, market and sell products based on its technology; the
expected benefits and efficacy of the Company’s products and technology
in connection with spinal cord injuries; the availability of substantial
additional funding for the Company to continue its operations and to
conduct research and development, clinical studies and future product
commercialization; and other risks associated with the Company’s
business, research, product development, regulatory approval, marketing
and distribution plans and strategies identified and described in more
detail in our filings with the SEC, including our Form 10-K and 10-Qs
and our current reports on Form 8-K. We do not undertake to update these
forward-looking statements made by us.
Copyright Business Wire 2013